Clinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid leukemia: A retrospective multicenter study

Basit Öğe Kaydı
dc.authoridalbayrak, murat/0000-0003-4025-741X
dc.authoridDogu, Mehmet Hilmi/0000-0001-7237-2637
dc.authoridBERBER, Ilhami/0000-0003-3312-8476;
dc.authorwosidalbayrak, murat/K-7879-2019
dc.authorwosidAyyildiz, Orhan/AEO-2377-2022
dc.authorwosidAlbayrak, Murat/JUU-5382-2023
dc.authorwosidDogu, Mehmet Hilmi/W-2255-2017
dc.authorwosidilhan, osman/ABC-8182-2021
dc.authorwosidBERBER, Ilhami/ABI-6231-2020
dc.authorwosidKorkmaz, Serdal/IST-3736-2023
dc.contributor.authorKorkmaz, Serdal
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorBerber, Ilhami
dc.contributor.authorSahin, Deniz Goren
dc.contributor.authorDogu, Mehmet Hilmi
dc.contributor.authorAyyildiz, Orhan
dc.contributor.authorNizam, Ilknur
dc.date.accessioned2024-08-04T20:40:17Z
dc.date.available2024-08-04T20:40:17Z
dc.date.issued2015
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAimsWe aimed to investigate whether older age leads to limitations in the starting dose of imatinib in daily treatment of chronic myeloid leukemia, and to determine the compliance of elderly patients with tyrosine kinase inhibitors (TKI) therapy. MethodsData including the clinical characteristics, therapeutic outcomes and compliance with TKI therapy of elderly patients with chronic myeloid leukemia aged >65years were collected from 13 institutions in Turkey, retrospectively. ResultsA total of 69 patients (27 [39%] men, 42 [61%] women) were evaluated retrospectively. The median age of the patients was 71years (range 66-85years). Of the patients, 66 (96%) were in the chronic phase and three (4.3%) were in the accelerated phase when diagnosed. A total of 63 (91.3%) patients were receiving imatinib as the first-line therapy. The initial dose of imatinib was 400mg/day in 59 patients (93.6%). Imatinib treatment induced 57 (90.5%) complete hematological responses at 3months, 29 (46%) complete cytogenetic responses at 6months and 49 (77.7%) major molecular responses at 12months. As a result, nilotinib and dasatinib were used in 14 patients as second-line therapy. Second-line TKI induced nine complete hematological responses (64.3%) at 3months, four complete cytogenetic responses (28.6%) at 12months and seven major molecular responses (50%) at 18months. A total of 56 of the patients (81.2%) are still alive. The median overall survival and progression-free survival rates were 35months (range 1-95months) and 17months (range 0.8-95months), respectively. ConclusionElderly patients should receive TKI according to the same guidelines that apply to younger patients. Geriatr Gerontol Int 2015; 15: 729-735.en_US
dc.identifier.doi10.1111/ggi.12341
dc.identifier.endpage735en_US
dc.identifier.issn1444-1586
dc.identifier.issn1447-0594
dc.identifier.issue6en_US
dc.identifier.pmid25257190en_US
dc.identifier.scopus2-s2.0-84930065678en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage729en_US
dc.identifier.urihttps://doi.org/10.1111/ggi.12341
dc.identifier.urihttps://hdl.handle.net/11616/96799
dc.identifier.volume15en_US
dc.identifier.wosWOS:000355733300008en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofGeriatrics & Gerontology Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectchronic myeloid leukemiaen_US
dc.subjectdasatiniben_US
dc.subjectelderly patientsen_US
dc.subjectimatiniben_US
dc.subjectnilotiniben_US
dc.titleClinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid leukemia: A retrospective multicenter studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu